Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (511-520 of 666) with videos related to

Pageof 67
Sort By:
ESC Heart Failure|February 27, 2020
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysisChristoph Wanner, Ulla Feldt-Rasmussen, Ana Jovanovic, et al.
Seminars in Dialysis|August 28, 2009
Conservative treatment of the uremic syndromeRaymond Vanholder, Angel Argilés, Joachim Beige, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2018
The impact of symptoms on health-related quality of life in elderly pre-dialysis patients: effect and importance in the EQUAL studyPauline W M Voskamp, Merel van Diepen, Marie Evans, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 16, 2018
Uraemic symptom burden and clinical condition in women and men of ≥65 years of age with advanced chronic kidney disease: results from the EQUAL studyMoniek W M van de Luijtgaarden, Fergus J Caskey, Christoph Wanner, et al.
Frontiers in Nephrology|October 30, 2024
Proceedings of a membrane update symposium: advancements, scientific insights, and future trends for dialysis membranes for enhanced clinical outcomes in end stage kidney disease patientsChristoph Wanner, Raymond Vanholder, Alberto Ortiz, et al.
Clinical Kidney Journal|January 12, 2024
Nephrology Partnership for Advancing Technology in Healthcare (N-PATH) program: the teachers' perspectiveCarlo Lomonte, Michele Rossini, Jose Ibeas, et al.
Scientific Reports|December 5, 2024
Monitoring individualized glucose levels predicts risk for bradycardia in type 2 diabetes patients with chronic kidney disease: a pilot studyPejman Farhadi Ghalati, Moein E Samadi, Marlo Verket, et al.
Diabetology International|March 25, 2020
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA<sup>®</sup> trialNobuya Inagaki, Wenying Yang, Hirotaka Watada, et al.
The Lancet. Diabetes & Endocrinology|November 20, 2020
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trialDarren K McGuire, Bernard Zinman, Silvio E Inzucchi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.
Pageof 67

Showing results (511-520 of 666) with videos related to

Sort By:
Pageof 67
ESC Heart Failure|February 27, 2020
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysisChristoph Wanner, Ulla Feldt-Rasmussen, Ana Jovanovic, et al.
Seminars in Dialysis|August 28, 2009
Conservative treatment of the uremic syndromeRaymond Vanholder, Angel Argilés, Joachim Beige, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2018
The impact of symptoms on health-related quality of life in elderly pre-dialysis patients: effect and importance in the EQUAL studyPauline W M Voskamp, Merel van Diepen, Marie Evans, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 16, 2018
Uraemic symptom burden and clinical condition in women and men of ≥65 years of age with advanced chronic kidney disease: results from the EQUAL studyMoniek W M van de Luijtgaarden, Fergus J Caskey, Christoph Wanner, et al.
Frontiers in Nephrology|October 30, 2024
Proceedings of a membrane update symposium: advancements, scientific insights, and future trends for dialysis membranes for enhanced clinical outcomes in end stage kidney disease patientsChristoph Wanner, Raymond Vanholder, Alberto Ortiz, et al.
Clinical Kidney Journal|January 12, 2024
Nephrology Partnership for Advancing Technology in Healthcare (N-PATH) program: the teachers' perspectiveCarlo Lomonte, Michele Rossini, Jose Ibeas, et al.
Scientific Reports|December 5, 2024
Monitoring individualized glucose levels predicts risk for bradycardia in type 2 diabetes patients with chronic kidney disease: a pilot studyPejman Farhadi Ghalati, Moein E Samadi, Marlo Verket, et al.
Diabetology International|March 25, 2020
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA<sup>®</sup> trialNobuya Inagaki, Wenying Yang, Hirotaka Watada, et al.
The Lancet. Diabetes & Endocrinology|November 20, 2020
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trialDarren K McGuire, Bernard Zinman, Silvio E Inzucchi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.
Pageof 67